<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01861054</url>
  </required_header>
  <id_info>
    <org_study_id>REP0210</org_study_id>
    <nct_id>NCT01861054</nct_id>
  </id_info>
  <brief_title>Pilot Study to Evaluate Safety &amp; Biological Effects of Orally Administered Reparixin in Early Breast Cancer</brief_title>
  <official_title>A Single Arm, Preoperative, Pilot Study to Evaluate the Safety and Biological Effects of Orally Administered Reparixin in Early Breast Cancer Patients Who Are Candidates for Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dompé Farmaceutici S.p.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dompé Farmaceutici S.p.A</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pilot &quot;window of opportunity&quot; clinical study in patients with operable breast&#xD;
      cancer investigating use of reparixin as single agent in the time period between clinical&#xD;
      diagnosis and surgery.&#xD;
&#xD;
      The primary objectives of this study were:&#xD;
&#xD;
      1- to evaluate the effects of orally administered reparixin on CSCs in the primary tumor and&#xD;
      the tumoral microenvironment in an early breast cancer population:&#xD;
&#xD;
      A. CSC were measured in tissue samples by techniques that could include: ALDEFLUOR assay and&#xD;
      assessment of CD44/CD24 by flow cytometry, or examination of RNA transcripts by RT-PCR,&#xD;
      aldehyde dehydrogenase-1, CD44/CD24 and epithelial mesenchymal transition markers (Snail,&#xD;
      Twist, Notch) by immunohistochemistry (IHC). CSC were defined as ALDEFLUOR positive (ALDH-1+)&#xD;
      and/or CD44 high/CD24 low by flow cytometry or RT-PCR and IHC and by the detection of ALDH-1+&#xD;
      cells with or without epithelial mesenchymal transition (EMT) transcription factor in IHC&#xD;
      assays.&#xD;
&#xD;
      B. Serine-threonine protein kinase (AKT), focal adhesion kinase (FAK), phosphatase and tensin&#xD;
      homolog (PTEN) and chemokine receptor-1 (CXCR1) levels were measured in tissue samples by&#xD;
      IHC.&#xD;
&#xD;
      C. Measurement of markers of inflammation (interleukin-1beta [IL-1β], interleukin-6 [IL-6],&#xD;
      interleukin-8 [IL-8], tumor necrosis factor-alpha [TNF-α], granulocyte macrophage colony&#xD;
      stimulating factor [GM-CSF], vascular endothelial growth factor [VEGF], basic fibroblast&#xD;
      growth factor [b-FGF] and high-sensitivity C-reactive protein [hsCRP]) in plasma, leukocyte&#xD;
      subsets (enumerate T subsets, B, and natural killer/natural killer T [NK/NKT] cells) and&#xD;
      study polymorphonuclear leukocyte [PMN] biology in peripheral blood samples. D. Measurement&#xD;
      of markers of angiogenesis (CD31 staining), tumor-infiltrating leukocytes (CD4, CD8, NK and&#xD;
      macrophages), autophagy (P62 and LC3 by IHC), EpCAM and EMT markers (CD326, CD45, Twist1,&#xD;
      SNAIL1, SLUG, ZEB1, FOXC2, TG2, Akt2, P13k and CK19 by RT-PCR) and tissue cellularity&#xD;
      (residual disease characterization in tumor bed) in tumor tissue samples.&#xD;
&#xD;
      2. To evaluate the safety of oral reparixin administered three times daily (t.i.d.) for 21&#xD;
      consecutive days.&#xD;
&#xD;
      The secondary objective was to define the pharmacokinetic (PK) profile of orally administered&#xD;
      reparixin.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      According to the cancer stem cell (CSC) model, tumors are organized in a cellular hierarchy&#xD;
      maintained by a subpopulation of cells displaying stem cell properties. These properties&#xD;
      include self-renewal (which drives tumorigenesis) and differentiation (which generates the&#xD;
      tumor bulk and contributes to cellular heterogeneity).&#xD;
&#xD;
      CSCs were first observed in hematological malignancies but have also been identified in solid&#xD;
      tumors of breast, prostate, brain, colon and pancreas. CSCs are thought to be resistant to&#xD;
      conventional chemotherapies and this may be why relapse occurs in many patients and this&#xD;
      might explain the failure to develop therapies that are consistently able to eradicate solid&#xD;
      tumors. Although currently available drugs can shrink metastatic tumors, these effects are&#xD;
      usually transient and often do not appreciably extend the life of patients. One reason for&#xD;
      the failure of these treatments is the acquisition of drug resistance by the cancer cells as&#xD;
      they evolve; another possibility is that existing therapies fail to kill CSCs effectively.&#xD;
      Existing therapies have been developed largely against the bulk population of tumor cells&#xD;
      because they are often identified by their ability to shrink tumors. Because most cancer&#xD;
      cells have limited proliferative potential, an ability to shrink a tumor mainly reflects an&#xD;
      ability to kill these cells. It seems that normal stem cells from various tissues tend to be&#xD;
      more resistant to chemotherapeutics than mature cell types from the same tissues. The reasons&#xD;
      for this are not clear, but may relate to high levels of expression of anti-apoptotic&#xD;
      proteins or adenosine triphosphate-binding cassette transporters such as the multidrug&#xD;
      resistance gene. If the same were true of CSCs, then one would predict that these cells would&#xD;
      be more resistant to chemotherapeutics than tumor cells with limited proliferative potential.&#xD;
      Even therapies that cause complete regression of tumors might spare enough CSCs to allow&#xD;
      re-growth of the tumors. Therapies that are more specifically directed against CSCs might&#xD;
      result in much more durable responses and even cures of metastatic tumors.&#xD;
&#xD;
      There are limited data on the impact of treatment tailoring based on CSC detection. Gene&#xD;
      profiling of CSCs could lead to identification of therapeutic targets on CSCs (e.g. hormone&#xD;
      receptors (HR), human epidermal growth factor receptor-2 [HER-2] expression, epidermal growth&#xD;
      factor receptor [EGFR] expression), and could represent tumor biopsy in &quot;real time&quot;. Several&#xD;
      groups showed frequent discordance of HER-2 status between primary tumor and CSCs, and case&#xD;
      reports showed clinical utility for the use of trastuzumab-based therapy based on HER-2 CSCs&#xD;
      status. Similarly, the hormonal status of CSCs could be different from that of the primary&#xD;
      tumor, which could lead to increase the number of patients suitable for endocrine therapy,&#xD;
      but also could explain why endocrine therapy fails in a subset of HR positive (HR+) patients.&#xD;
      More specifically, a recent observation from Ginestier et al. demonstrated that over&#xD;
      expression of chemokine receptor 1 (CXCR-1) is associated with the aldehyde dehydrogenase&#xD;
      positive (ALDH+) cells. In breast carcinomas, the ALDEFLUOR+ phenotype shows partial overlap&#xD;
      with the CD44+CD24-Lin-CSC phenotype. Cellular hierarchies have been identified in a series&#xD;
      of molecularly characterized breast cancer cell lines and it has been demonstrated that these&#xD;
      lines contained ALDEFLUOR+ components that were both tumorigenic and metastatic in NOD/SCID&#xD;
      mice. Furthermore, previous observations demonstrated that the addition of recombinant&#xD;
      interleukin-8 (IL-8) increased the CSC population as well as increasing its propensity for&#xD;
      invasion. Moreover, tissue damage induced by chemotherapeutic agents may induce IL-8 as part&#xD;
      of the injury response. This suggests that strategies aimed at interfering with the IL&#xD;
      8/CXCR-1 axis may be able to target CSCs, increasing the efficacy of current therapies. This&#xD;
      experimental data provides another therapeutic target in breast cancer.&#xD;
&#xD;
      Reparixin seems to be a good candidate for use in breast cancer patients because of its very&#xD;
      acceptable toxicity profile shown in the Phase I and II clinical trials conducted so far,&#xD;
      along with its observed activity in vitro against breast cancer cell lines and in vivo in&#xD;
      tumor xenografts in mice. A phase 1 study is currently underway to study the effects of&#xD;
      reparixin in combination with paclitaxel in metastatic breast cancer.&#xD;
&#xD;
      This small pilot study aims at exploring the effects on breast CSC markers as well as the&#xD;
      safety and PK profile of orally administered single agent reparixin in HER-2 negative&#xD;
      (HER-2-) early breast cancer patients in the 3 weeks prior to surgery.&#xD;
&#xD;
      The study will be performed in the interval between disease diagnosis and planned surgery and&#xD;
      may lead to a minimal delay in surgery. This is balanced by the potential benefits of the&#xD;
      study by evaluating CSCs and their prognostic importance as well as obtaining information&#xD;
      about the impact of reparixin therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Enrollment target not reached&#xD;
  </why_stopped>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">March 1, 2016</completion_date>
  <primary_completion_date type="Actual">March 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline to Day 21 in Markers of Cancer Stem Cells (CSCs) in the Primary Tumor and the Tumoral Microenvironment (ALDH1,CD44/CD24)</measure>
    <time_frame>At day 21</time_frame>
    <description>CSCs were measured in tissue samples by the following techniques: ALDH-1 by ALDEFLUOR and by immunohistochemistry (IHC); CD44/CD24 by flow cytometry or examination of RNA transcripts by RT-PCR and by immunohistochemistry (IHC); epithelial mesenchymal markers (Snail, Twist, Notch) by immunohistochemistry (IHC).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline-1 to Day 21-1 in Pathway Markers by IHC</measure>
    <time_frame>Day 21 (or last day of treatment)</time_frame>
    <description>Pathway markers (AKT, FAK, PTEN and CXCR1) were measured in tissue samples at the pre-study (Day -14 to 0) and Day 21 (or within 24 hours of last dose). For the evaluation of the stain extent, the following semi-quantitative score method (0 to 4) was used: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Hence for this scale, the higher the values, the worse is the outcome. For the evaluation of the stain intensity, the following score method (0 to 3) was used: 0, negative; 1, weak; 2, moderate, 3; strong. Also for this scale, the higher the score, the worse the outcome.&#xD;
Serine-threonine protein kinase (AKT, also known as protein kinase B, PKB) Focal adhesion kinase (FAK) Chemokine receptor-1 (CXCR1)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline to Day 21 in Markers of Inflammation</measure>
    <time_frame>At Day 21</time_frame>
    <description>Markers of inflammation (IL-1β, IL-6, IL-8, TNF-α, GM-CSF, VEGF, and b-FGF) were measured in plasma from peripheral blood.&#xD;
IL = interleukins TNF-α = tumor necrosis factor-alpha GM-CSF = macrophage colony stimulating factor VEGF = vascular endothelial growth factor b-FGF = basic fibroblast growth factor</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline-1 to Day 21-1 in Markers of Angiogenesis (CD31 Staining)</measure>
    <time_frame>At day 21</time_frame>
    <description>CD31 staining by IHC. For the evaluation of the stain extent, the following semi-quantitative score method (0 to 4) was used: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Hence for this scale, the higher the values, the worse is the outcome. For the evaluation of the stain intensity, the following score method (0 to 3) was used: 0, negative; 1, weak; 2, moderate, 3; strong. Also for this scale, the higher the score, the worse the outcome.&#xD;
CD31 is a transmembrane glycoprotein, 130-140 kDa, also know as platelet-endothelium cell adhesion molecule (PECAM-1). CD31 is ligand for CD38 and plays a role in thrombosis and angiogenesis. CD31 is strongly expressed in endothelial cells and weakly expressed in megakaryocytes, platelets, occasional plasma cells, lymphocytes (espc. marginal zone B-cells, peripheral T-cells) and neutrophils.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline-1 to Day 21-1 in Markers of Autophagy (P62 and LC3B by IHC)</measure>
    <time_frame>At day 21</time_frame>
    <description>Autophagy is a lysosomal degradation and recycling process implicated in cancer progression and therapy resistance. Labeling of p62 serves as a useful marker for the induction of autophagy, clearance of protein aggregates, and the inhibition of autophagy. Labeling of LC3B serves to track the binding of p62 and subsequent recruitment of autophagosomes.&#xD;
For the evaluation of the extent, the following semi-quantitative score method (0 to 4) was used: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Hence for this scale, the higher the values, the worse is the outcome. For the evaluation of the intensity, the following score method (0 to 3) was used: 0, negative; 1, weak; 2, moderate, 3; strong. Also for this scale, the higher the score, the worse the outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - Cmax</measure>
    <time_frame>At Days 1 (pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose) and 21(pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose)</time_frame>
    <description>Once absorbed, reparixin is highly protein bound. By comparing Cmax and AUC for unbound drug to that for total drug, only &lt; 0.1% to 0.2% of reparixin is available as unbound (free) drug. The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
Cmax = Maximum plasma concentration obtained directly from the data without interpolation, expressed in concentration units</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - Tmax and T1/2</measure>
    <time_frame>At Days 1 (pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose) and 21(pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose)</time_frame>
    <description>Once absorbed, reparixin is highly protein-bound. By comparing Cmax and AUC for unbound drug to that for total drug, only &lt; 0.1% to 0.2% of reparixin is available as unbound (free) drug. The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
tmax = Time to reach the maximum plasma concentration obtained directly from the data without interpolation t1/2 = Terminal elimination half-life calculated as ln(2)/ lambda z; calculated only if the coefficient of determination R2 in lambda z estimation is at least 0.8.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - AUC0-8, AUCinf, AUClast, AUCtau at Day 21,</measure>
    <time_frame>At Days 1 (pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose) and 21(pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose)</time_frame>
    <description>The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
AUC0-8 = The area under the plasma concentration-time curve from time 0 to 8 hours post-dose; AUClast = The area under the concentration-time curve from time 0 to last quantifiable concentration AUCtau = The area under the plasma concentration-time curve for dosing interval (dosing interval [tau] = 8 hours); AUCinf = The total area under the plasma concentration-time curve from time zero to time infinity; AUC0-inf = AUClast + Clast/lambda zeta, where Clast is the last observed concentration ≥ lower limit of quantitation at time tlast.&#xD;
All these parameters were calculated by the linear trapezoidal rule.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - CL/F (L/h) at Day 1, CLSS/F (L/h) Day 21)</measure>
    <time_frame>At Days 1 (pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose) and 21(pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose)</time_frame>
    <description>The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
CL/F = Apparent oral clearance - for DF1681Y only, calculated as dose/AUCinf.; calculated only when the coefficient of determination R2 in lambda zeta estimation is at least 0.8 and percent AUC extrapolation is less than or equal to 20%.&#xD;
CLss/F = Steady state apparent oral clearance - for DF1681Y only calculated as dose/AUCtau.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline to Day 21 in Leukocytes Subsets</measure>
    <time_frame>At Day 21</time_frame>
    <description>The Leukocytes subsets analyzed are the following: Lymphocyte in WBC, Total T cell in lymphocytes, B cells in lymphocytes, T-helper cell in lymphocytes, CTL in lymphocytes, NKT cell in lymphocytes, ADCC NK subsets in lymphocytes, Regulatory NK subsets in lymphocytes, Exhausted NK subsets in lymphocytes, CD56-CD16+ NK subsets in lymphocytes, CD11b in PMNs - IL-8, CD18 in PMNs - IL-8, MFI of CD11b - IL-8, MFI of CD66b - IL-8, MFI of CD18 - IL-8, CD11b in PMNs - US, CD18 in PMNs - US, MFI of CD11b - US, MFI of CD66b - US, MFI of CD18 - US, Percent Monocytes expressing IL6 - IL-8,Percent Monocytes expressing IL1b - IL-8, Percent Monocytes expressing IL8 - IL-8, Percent Monocytes expressing TNFa - IL-8, Percent Neutrophils expressing IL6 - IL-8, Percent Neutrophils expressing IL1b - IL-8, Percent Neutrophils expressing IL8 - IL-8, Percent Neutrophils expressing TNFa - IL-8,Percent Monocytes expressing IL6 - US,Percent Monocytes expressing IL1b - US, etc.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Treated patients - Total</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients eligible will be treated with Reparixin as add-in monotherapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Reparixin</intervention_name>
    <description>1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery</description>
    <arm_group_label>Treated patients - Total</arm_group_label>
    <other_name>REP</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female aged &gt; 18 years.&#xD;
&#xD;
          -  Patients with operable breast cancer, with measurable tumors of more than 1 cm in&#xD;
             diameter, that are not candidates for neoadjuvant therapy.&#xD;
&#xD;
          -  Zubrod (Eastern Co-operative Oncology Group [ECOG]) Performance Status (PS) of 0-1.&#xD;
&#xD;
          -  No prior treatment by surgery, radiotherapy, hormone therapy e.g. TAMOXIFEN® or&#xD;
             RALOXIFEN® for prevention or chemotherapy.&#xD;
&#xD;
          -  Scheduled to undergo definitive local surgery for breast cancer.&#xD;
&#xD;
          -  Patients must be willing to undergo two mandatory tumor biopsies (pre and post&#xD;
             therapy) that are not required for standard care. A sample of tumor tissue removed&#xD;
             during surgery will also be collected for analysis.&#xD;
&#xD;
          -  Patients must be able to swallow and retain oral medication (intact tablet).&#xD;
&#xD;
          -  Able to undergo all screening assessments outlined in the protocol after giving&#xD;
             informed consent.&#xD;
&#xD;
          -  Adequate organ function (defined by the following parameters):&#xD;
&#xD;
               1. Serum creatinine &lt; 140 μmol/L or creatinine clearance &gt; 60 mL/min.&#xD;
&#xD;
               2. Serum hemoglobin &gt; 9 g/dL; absolute neutrophil count &gt; 1.5 x 109/L; platelets &gt;&#xD;
                  100 x 109/L.&#xD;
&#xD;
               3. Serum bilirubin &lt; upper normal limit (UNL).&#xD;
&#xD;
               4. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST) ≤ UNL;&#xD;
                  alkaline phosphatase (ALP) ≤ UNL; albumin within normal limits.&#xD;
&#xD;
          -  Documented hormone receptor (ER and progesterone receptor) and HER-2- status.&#xD;
&#xD;
          -  No known hepatitis B virus (unless due to immunization), hepatitis C virus, human&#xD;
             immune deficiency virus-I and II positive status.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Male.&#xD;
&#xD;
          -  Pregnancy or lactation or unwillingness to use two adequate methods of birth control&#xD;
             throughout the study and for 30 days after study discontinuation.&#xD;
&#xD;
          -  Any other breast cancer types including inflammatory form.&#xD;
&#xD;
          -  Prior surgery to the breast area or primary axillary dissection.&#xD;
&#xD;
          -  Prior treatment for breast cancer.&#xD;
&#xD;
          -  Use of an investigational drug within 30 days preceding the first dose of study&#xD;
             medication.&#xD;
&#xD;
          -  Any prior or current cancer, except in situ uterine carcinoma or basocellular&#xD;
             cutaneous cancer considered as definitively cured.&#xD;
&#xD;
          -  Any associated medical condition considered incompatible with the study, e.g. cardiac,&#xD;
             renal, medullar, respiratory or hepatic insufficiency.&#xD;
&#xD;
          -  Neurological or psychiatric disorders which may influence understanding of study and&#xD;
             informed consent procedures.&#xD;
&#xD;
          -  Active or uncontrolled infection.&#xD;
&#xD;
          -  Malabsorption syndrome, disease significantly affecting gastrointestinal function.&#xD;
&#xD;
          -  Hypersensitivity to:&#xD;
&#xD;
               1. ibuprofen or to more than one non-steroidal anti-inflammatory drug;&#xD;
&#xD;
               2. medications belonging to the class of sulfonamides, such as sulfamethazine,&#xD;
                  sulfamethoxazole, sulfasalazine, nimesulide or celecoxib.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lori J Goldstein, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fox Chase Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Indiana University Simon Cancer Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202-5289</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Kansas Cancer Center, 4350 Shawnee Mission Pkwy, Suite 1500, Mailstop 6004</name>
      <address>
        <city>Fairway</city>
        <state>Kansas</state>
        <zip>66205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Cancer Institute of New Jersey</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Montefiore Medical Center, MMC Medical Park at Eastchester</name>
      <address>
        <city>Bronx</city>
        <state>New York</state>
        <zip>10461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Weill Cornell Medical College</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fox Chase Cancer Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee-Womens Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sara Cannon Research Institute</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Methodist Hospital Research Institute</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6954543/</url>
    <description>Goldstein LJ Breast Cancer Research 22:4. doi: 10.1186/s13058-019-1243-8, 2020</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 18, 2013</study_first_submitted>
  <study_first_submitted_qc>May 21, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 23, 2013</study_first_posted>
  <results_first_submitted>February 4, 2021</results_first_submitted>
  <results_first_submitted_qc>March 2, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 25, 2021</results_first_posted>
  <last_update_submitted>April 15, 2021</last_update_submitted>
  <last_update_submitted_qc>April 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cancer Stem Cells</keyword>
  <keyword>Novel targeted therapy</keyword>
  <keyword>CXCR1/2 Inhibitors</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients recruitment: before initiating a study, the Investigator was required to have written and dated approval from the Institutional Review Board (IRB)/Independent Ethics Committee (IEC) for the study protocol, written informed consent form (ICF), consent form updates, subject recruitment procedures (e.g., advertisements), and any other written information to be provided to subjects.</recruitment_details>
      <pre_assignment_details>It was planned to enroll 2 sub-groups of patients into the study, Group A: ER+ and/or PR+/HER-2- and Group B: ER-/PR-/HER-2-, and the sample size of 20 patients per group was chosen. Twenty patients in total were enrolled, 18 in Group A and 2 in Group B. The study was closed prematurely due to slow enrollment in group B. All 20 patients were included in the Safety Population and 6 (30%) were included in the PK population. All 20 patients completed the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ER+ and/or PR+/ HER-2 -</title>
          <description>Patients of Group A (estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)/human epidermal growth factor receptor-2 negative (HER-2-)) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack.</description>
        </group>
        <group group_id="P2">
          <title>ER-/PR-/HER-2-</title>
          <description>Patients of Group B (estrogen receptor negative (ER-)/progesterone receptor negative (PR-)/HER-2-) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Safety Population</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>PK Population</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ER+ and/or PR+/ HER-2 -</title>
          <description>Patients of Group A (estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)/human epidermal growth factor receptor-2 negative (HER-2-)) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
        </group>
        <group group_id="B2">
          <title>ER-/PR-/HER-2-</title>
          <description>Patients of Group B (estrogen receptor negative (ER-)/progesterone receptor negative (PR-)/HER-2-) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="2"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.0" spread="8.92"/>
                    <measurement group_id="B2" value="56.5" spread="12.02"/>
                    <measurement group_id="B3" value="54.3" spread="8.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 21 in Markers of Cancer Stem Cells (CSCs) in the Primary Tumor and the Tumoral Microenvironment (ALDH1,CD44/CD24)</title>
        <description>CSCs were measured in tissue samples by the following techniques: ALDH-1 by ALDEFLUOR and by immunohistochemistry (IHC); CD44/CD24 by flow cytometry or examination of RNA transcripts by RT-PCR and by immunohistochemistry (IHC); epithelial mesenchymal markers (Snail, Twist, Notch) by immunohistochemistry (IHC).</description>
        <time_frame>At day 21</time_frame>
        <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ER+ and/or PR+/ HER-2 -</title>
            <description>Patients of Group A (estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)/human epidermal growth factor receptor-2 negative (HER-2-)) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
          <group group_id="O2">
            <title>ER-/PR-/HER-2-</title>
            <description>Patients of Group B (estrogen receptor negative (ER-)/progesterone receptor negative (PR-)/HER-2-) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 21 in Markers of Cancer Stem Cells (CSCs) in the Primary Tumor and the Tumoral Microenvironment (ALDH1,CD44/CD24)</title>
          <description>CSCs were measured in tissue samples by the following techniques: ALDH-1 by ALDEFLUOR and by immunohistochemistry (IHC); CD44/CD24 by flow cytometry or examination of RNA transcripts by RT-PCR and by immunohistochemistry (IHC); epithelial mesenchymal markers (Snail, Twist, Notch) by immunohistochemistry (IHC).</description>
          <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis</population>
          <units>percentage of cells</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALDH+</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.34" spread="2.737"/>
                    <measurement group_id="O2" value="-0.40" spread="1.131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD44+/CD24-</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.57" spread="5.617"/>
                    <measurement group_id="O2" value="0.20" spread="1.273"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison on ALDH+ cells by ALDEFLUOR assay</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3149</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Comparison on CD44+/CD24- by flow citometry</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8148</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline-1 to Day 21-1 in Pathway Markers by IHC</title>
        <description>Pathway markers (AKT, FAK, PTEN and CXCR1) were measured in tissue samples at the pre-study (Day -14 to 0) and Day 21 (or within 24 hours of last dose). For the evaluation of the stain extent, the following semi-quantitative score method (0 to 4) was used: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Hence for this scale, the higher the values, the worse is the outcome. For the evaluation of the stain intensity, the following score method (0 to 3) was used: 0, negative; 1, weak; 2, moderate, 3; strong. Also for this scale, the higher the score, the worse the outcome.&#xD;
Serine-threonine protein kinase (AKT, also known as protein kinase B, PKB) Focal adhesion kinase (FAK) Chemokine receptor-1 (CXCR1)</description>
        <time_frame>Day 21 (or last day of treatment)</time_frame>
        <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ER+ and/or PR+/ HER-2 -</title>
            <description>Patients of Group A (estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)/human epidermal growth factor receptor-2 negative (HER-2-)) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
          <group group_id="O2">
            <title>ER-/PR-/HER-2-</title>
            <description>Patients of Group B (estrogen receptor negative (ER-)/progesterone receptor negative (PR-)/HER-2-) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline-1 to Day 21-1 in Pathway Markers by IHC</title>
          <description>Pathway markers (AKT, FAK, PTEN and CXCR1) were measured in tissue samples at the pre-study (Day -14 to 0) and Day 21 (or within 24 hours of last dose). For the evaluation of the stain extent, the following semi-quantitative score method (0 to 4) was used: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Hence for this scale, the higher the values, the worse is the outcome. For the evaluation of the stain intensity, the following score method (0 to 3) was used: 0, negative; 1, weak; 2, moderate, 3; strong. Also for this scale, the higher the score, the worse the outcome.&#xD;
Serine-threonine protein kinase (AKT, also known as protein kinase B, PKB) Focal adhesion kinase (FAK) Chemokine receptor-1 (CXCR1)</description>
          <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stain Phospho-AKT Extent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain Phospho-AKT Intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain AKT Extent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-4" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain AKT Intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-3" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospho-FAK Extent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phospho-FAK Intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="2"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-1" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain FAK Extent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain FAK Intens</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain C-PTEN Extent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-4" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain C-PTEN Intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain D-PTEN Extent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-4" upper_limit="2"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain D-PTEN Intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain CXCR1 Extent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-4" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain CXCR1 Intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.5" lower_limit="-3" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phospho AKT Extent</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phospho-AKT Intensity</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AKT Extent</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2245</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>AKT Intensity</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5785</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phospho-FAK Extent</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Phospho-FAK Intensity</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3139</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FAK Extent</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2120</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>FAK Intensity</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>C-PTEN Extent</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>C-PTEN Intensity</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8728</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>D-PTEN Extent</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>D-PTEN Intensity</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8728</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CXCR1 Extent</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2265</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CXCR1 Intensity</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2403</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline to Day 21 in Markers of Inflammation</title>
        <description>Markers of inflammation (IL-1β, IL-6, IL-8, TNF-α, GM-CSF, VEGF, and b-FGF) were measured in plasma from peripheral blood.&#xD;
IL = interleukins TNF-α = tumor necrosis factor-alpha GM-CSF = macrophage colony stimulating factor VEGF = vascular endothelial growth factor b-FGF = basic fibroblast growth factor</description>
        <time_frame>At Day 21</time_frame>
        <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ER+ and/or PR+/ HER-2 -</title>
            <description>Patients of Group A (estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)/human epidermal growth factor receptor-2 negative (HER-2-)) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
          <group group_id="O2">
            <title>ER-/PR-/HER-2-</title>
            <description>Patients of Group B (estrogen receptor negative (ER-)/progesterone receptor negative (PR-)/HER-2-) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 21 in Markers of Inflammation</title>
          <description>Markers of inflammation (IL-1β, IL-6, IL-8, TNF-α, GM-CSF, VEGF, and b-FGF) were measured in plasma from peripheral blood.&#xD;
IL = interleukins TNF-α = tumor necrosis factor-alpha GM-CSF = macrophage colony stimulating factor VEGF = vascular endothelial growth factor b-FGF = basic fibroblast growth factor</description>
          <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis.</population>
          <units>pg/ML</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Interleukin 1 Beta</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.019" spread="30.3118"/>
                    <measurement group_id="O2" value="0" spread="0.000"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.593" spread="39.2733"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Interleukin 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-25.874" spread="134.3213"/>
                    <measurement group_id="O2" value="29.320" spread="41.6910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TNFα</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.669" spread="8.0313"/>
                    <measurement group_id="O2" value="-0.890" spread="3.5780"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GM-CSF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.678" spread="8.2154"/>
                    <measurement group_id="O2" value="8.705" spread="12.3107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>VEGF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="253.584" spread="1120.6125"/>
                    <measurement group_id="O2" value="27.635" spread="39.0818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>b-FGF</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.164" spread="93.4614"/>
                    <measurement group_id="O2" value="-9.750" spread="13.7886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 1 Beta</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 6</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6945</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Interleukin 8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9448</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Tumor Necrosis Factor - alpha</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6292</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Granulocyte Macrophage Colony Stm Factor</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2354</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Vascular Endothelial Growth Factor</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Basic Fibroblast Growth Factor</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4719</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline-1 to Day 21-1 in Markers of Angiogenesis (CD31 Staining)</title>
        <description>CD31 staining by IHC. For the evaluation of the stain extent, the following semi-quantitative score method (0 to 4) was used: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Hence for this scale, the higher the values, the worse is the outcome. For the evaluation of the stain intensity, the following score method (0 to 3) was used: 0, negative; 1, weak; 2, moderate, 3; strong. Also for this scale, the higher the score, the worse the outcome.&#xD;
CD31 is a transmembrane glycoprotein, 130-140 kDa, also know as platelet-endothelium cell adhesion molecule (PECAM-1). CD31 is ligand for CD38 and plays a role in thrombosis and angiogenesis. CD31 is strongly expressed in endothelial cells and weakly expressed in megakaryocytes, platelets, occasional plasma cells, lymphocytes (espc. marginal zone B-cells, peripheral T-cells) and neutrophils.</description>
        <time_frame>At day 21</time_frame>
        <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ER+ and/or PR+/ HER-2 -</title>
            <description>Patients of Group A (estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)/human epidermal growth factor receptor-2 negative (HER-2-)) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
          <group group_id="O2">
            <title>ER-/PR-/HER-2-</title>
            <description>Patients of Group B (estrogen receptor negative (ER-)/progesterone receptor negative (PR-)/HER-2-) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline-1 to Day 21-1 in Markers of Angiogenesis (CD31 Staining)</title>
          <description>CD31 staining by IHC. For the evaluation of the stain extent, the following semi-quantitative score method (0 to 4) was used: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Hence for this scale, the higher the values, the worse is the outcome. For the evaluation of the stain intensity, the following score method (0 to 3) was used: 0, negative; 1, weak; 2, moderate, 3; strong. Also for this scale, the higher the score, the worse the outcome.&#xD;
CD31 is a transmembrane glycoprotein, 130-140 kDa, also know as platelet-endothelium cell adhesion molecule (PECAM-1). CD31 is ligand for CD38 and plays a role in thrombosis and angiogenesis. CD31 is strongly expressed in endothelial cells and weakly expressed in megakaryocytes, platelets, occasional plasma cells, lymphocytes (espc. marginal zone B-cells, peripheral T-cells) and neutrophils.</description>
          <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stain CD31 Extent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain CD31 Intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1" upper_limit="1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="1" upper_limit="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD31 Extent</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0951</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD31 Intensity</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1643</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline-1 to Day 21-1 in Markers of Autophagy (P62 and LC3B by IHC)</title>
        <description>Autophagy is a lysosomal degradation and recycling process implicated in cancer progression and therapy resistance. Labeling of p62 serves as a useful marker for the induction of autophagy, clearance of protein aggregates, and the inhibition of autophagy. Labeling of LC3B serves to track the binding of p62 and subsequent recruitment of autophagosomes.&#xD;
For the evaluation of the extent, the following semi-quantitative score method (0 to 4) was used: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Hence for this scale, the higher the values, the worse is the outcome. For the evaluation of the intensity, the following score method (0 to 3) was used: 0, negative; 1, weak; 2, moderate, 3; strong. Also for this scale, the higher the score, the worse the outcome.</description>
        <time_frame>At day 21</time_frame>
        <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>ER+ and/or PR+/ HER-2 -</title>
            <description>Patients of Group A (estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)/human epidermal growth factor receptor-2 negative (HER-2-)) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
          <group group_id="O2">
            <title>ER-/PR-/HER-2-</title>
            <description>Patients of Group B (estrogen receptor negative (ER-)/progesterone receptor negative (PR-)/HER-2-) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline-1 to Day 21-1 in Markers of Autophagy (P62 and LC3B by IHC)</title>
          <description>Autophagy is a lysosomal degradation and recycling process implicated in cancer progression and therapy resistance. Labeling of p62 serves as a useful marker for the induction of autophagy, clearance of protein aggregates, and the inhibition of autophagy. Labeling of LC3B serves to track the binding of p62 and subsequent recruitment of autophagosomes.&#xD;
For the evaluation of the extent, the following semi-quantitative score method (0 to 4) was used: 0, no positive cells; 1, 1-25%; 2, 26-50%; 3, 51-75%; and 4, 76-100%. Hence for this scale, the higher the values, the worse is the outcome. For the evaluation of the intensity, the following score method (0 to 3) was used: 0, negative; 1, weak; 2, moderate, 3; strong. Also for this scale, the higher the score, the worse the outcome.</description>
          <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis.</population>
          <units>score on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="18"/>
                <count group_id="O2" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Stain P62 Extent</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.0" lower_limit="-3" upper_limit="1"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stain P62 Intensity</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-2" upper_limit="0"/>
                    <measurement group_id="O2" value="-1.0" lower_limit="-1" upper_limit="-1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P62 Extent</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4183</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>P62 Intensity</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3702</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - Cmax</title>
        <description>Once absorbed, reparixin is highly protein bound. By comparing Cmax and AUC for unbound drug to that for total drug, only &lt; 0.1% to 0.2% of reparixin is available as unbound (free) drug. The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
Cmax = Maximum plasma concentration obtained directly from the data without interpolation, expressed in concentration units</description>
        <time_frame>At Days 1 (pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose) and 21(pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose)</time_frame>
        <population>The PK Population consisted of patients who received at least one dose of reparixin and had at least one valid, quantifiable PK parameter. This population was used for PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients - Total</title>
            <description>Patients eligible were treated with Reparixin as add-in monotherapy&#xD;
Reparixin: 1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - Cmax</title>
          <description>Once absorbed, reparixin is highly protein bound. By comparing Cmax and AUC for unbound drug to that for total drug, only &lt; 0.1% to 0.2% of reparixin is available as unbound (free) drug. The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
Cmax = Maximum plasma concentration obtained directly from the data without interpolation, expressed in concentration units</description>
          <population>The PK Population consisted of patients who received at least one dose of reparixin and had at least one valid, quantifiable PK parameter. This population was used for PK analyses.</population>
          <units>micrograms/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day1 - DF1681Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.925" spread="31.5024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day21 - DF1681Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.927" spread="15.7616"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 - DF1681Y unbound</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145.167" spread="116.6114"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day21 - DF1681Y unbound</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136.552" spread="104.8681"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - DF2243Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.788" spread="2.5240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 - DF2243Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.812" spread="9.9776"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - DF2188Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.302" spread="1.5129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 - DF2188Y</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.367" spread="4.3439"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - Tmax and T1/2</title>
        <description>Once absorbed, reparixin is highly protein-bound. By comparing Cmax and AUC for unbound drug to that for total drug, only &lt; 0.1% to 0.2% of reparixin is available as unbound (free) drug. The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
tmax = Time to reach the maximum plasma concentration obtained directly from the data without interpolation t1/2 = Terminal elimination half-life calculated as ln(2)/ lambda z; calculated only if the coefficient of determination R2 in lambda z estimation is at least 0.8.</description>
        <time_frame>At Days 1 (pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose) and 21(pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose)</time_frame>
        <population>The PK Population consisted of patients who received at least one dose of reparixin and had at least one valid, quantifiable PK parameter. This population was used for PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients - Total</title>
            <description>Patients eligible will be treated with Reparixin as add-in monotherapy&#xD;
Reparixin: 1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - Tmax and T1/2</title>
          <description>Once absorbed, reparixin is highly protein-bound. By comparing Cmax and AUC for unbound drug to that for total drug, only &lt; 0.1% to 0.2% of reparixin is available as unbound (free) drug. The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
tmax = Time to reach the maximum plasma concentration obtained directly from the data without interpolation t1/2 = Terminal elimination half-life calculated as ln(2)/ lambda z; calculated only if the coefficient of determination R2 in lambda z estimation is at least 0.8.</description>
          <population>The PK Population consisted of patients who received at least one dose of reparixin and had at least one valid, quantifiable PK parameter. This population was used for PK analyses.</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day1 - DF1681Y tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.667" spread="2.8752"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day21 - DF1681Y tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.997" spread="0.5508"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 - DF1681Y unbound tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.583" spread="1.2813"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day21 - DF1681Y unbound tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.092" spread="0.4903"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - DF2243Y tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.333" spread="2.3381"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 - DF2243Y tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.331" spread="0.8179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - DF2188Y tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.500" spread="1.2247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 - DF2188Y tmax</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.508" spread="0.5389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 - DF1681Y t1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.090" spread="0.9847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day21 - DF1681Y t1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.626" spread="0.4068"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day1 - DF1681Y unbound t1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.403" spread="0.4592"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day21 - DF1681Y unbound t1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.989" spread="0.1683"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - DF2243Y t1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.913" spread="0.3268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 - DF2243Y t1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.575" spread="0.6442"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 1 - DF2188Y t1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.035" spread="1.0618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21 - DF2188Y t1/2</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.575" spread="0.1953"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - AUC0-8, AUCinf, AUClast, AUCtau at Day 21,</title>
        <description>The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
AUC0-8 = The area under the plasma concentration-time curve from time 0 to 8 hours post-dose; AUClast = The area under the concentration-time curve from time 0 to last quantifiable concentration AUCtau = The area under the plasma concentration-time curve for dosing interval (dosing interval [tau] = 8 hours); AUCinf = The total area under the plasma concentration-time curve from time zero to time infinity; AUC0-inf = AUClast + Clast/lambda zeta, where Clast is the last observed concentration ≥ lower limit of quantitation at time tlast.&#xD;
All these parameters were calculated by the linear trapezoidal rule.</description>
        <time_frame>At Days 1 (pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose) and 21(pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose)</time_frame>
        <population>The PK Population consisted of patients who received at least one dose of reparixin and had at least one valid, quantifiable PK parameter. This population was used for PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients - Total</title>
            <description>Patients eligible will be treated with Reparixin as add-in monotherapy&#xD;
Reparixin: 1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - AUC0-8, AUCinf, AUClast, AUCtau at Day 21,</title>
          <description>The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
AUC0-8 = The area under the plasma concentration-time curve from time 0 to 8 hours post-dose; AUClast = The area under the concentration-time curve from time 0 to last quantifiable concentration AUCtau = The area under the plasma concentration-time curve for dosing interval (dosing interval [tau] = 8 hours); AUCinf = The total area under the plasma concentration-time curve from time zero to time infinity; AUC0-inf = AUClast + Clast/lambda zeta, where Clast is the last observed concentration ≥ lower limit of quantitation at time tlast.&#xD;
All these parameters were calculated by the linear trapezoidal rule.</description>
          <population>The PK Population consisted of patients who received at least one dose of reparixin and had at least one valid, quantifiable PK parameter. This population was used for PK analyses.</population>
          <units>h*μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DF1681Y - AUC0-8 - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.357" spread="60.2362"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y - AUC0-8 - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.303" spread="29.8012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y unbound- AUC0-8 - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.602" spread="128.0328"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y unbound- AUC0-8 - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.382" spread="166.0402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2243Y - AUC0-8 - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.469" spread="18.8116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2243Y - AUC0-8 - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.001" spread="58.2634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2188Y - AUC0-8 - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.040" spread="7.9369"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2188Y - AUC0-8 - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.395" spread="13.2129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y - AUCinf - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="211.243" spread="71.4823"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y - AUCinf - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="182.479" spread="36.1551"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y unbound - AUCinf - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="235.152" spread="180.1547"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y unbound - AUCinf - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.547" spread="166.3017"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2243Y - AUCinf - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="71.297" spread="25.6857"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2243Y - AUCinf - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="129.275" spread="74.5406"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2188Y - AUCinf - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.669" spread="11.2792"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2188Y - AUCinf - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.092" spread="13.9473"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y - AUClast - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="189.319" spread="60.2817"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y - AUClast - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="172.296" spread="28.1847"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y unbound - AUClast - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.078" spread="128.1305"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y unbound - AUClast - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.235" spread="167.0377"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2243Y - AUClast - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.821" spread="17.3033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2243Y - AUClast - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.360" spread="46.6809"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2188Y - AUClast - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.028" spread="7.9336"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2188Y - AUClast - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.433" spread="12.8434"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y - AUCtau - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="174.303" spread="29.8012"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y unbound - AUCtau - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="233.382" spread="166.0402"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2243Y - AUCtau - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.001" spread="58.2634"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF2188Y - AUCtau - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.395" spread="13.2129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - CL/F (L/h) at Day 1, CLSS/F (L/h) Day 21)</title>
        <description>The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
CL/F = Apparent oral clearance - for DF1681Y only, calculated as dose/AUCinf.; calculated only when the coefficient of determination R2 in lambda zeta estimation is at least 0.8 and percent AUC extrapolation is less than or equal to 20%.&#xD;
CLss/F = Steady state apparent oral clearance - for DF1681Y only calculated as dose/AUCtau.</description>
        <time_frame>At Days 1 (pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose) and 21(pre-first dose and 0.25, 0.5, 1, 2, 4, 6, 8h post dose)</time_frame>
        <population>The PK Population consisted of patients who received at least one dose of reparixin and had at least one valid, quantifiable PK parameter. This population was used for PK analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>Treated Patients - Total</title>
            <description>Patients eligible will be treated with Reparixin as add-in monotherapy&#xD;
Reparixin: 1000 mg Oral Reparixin t.i.d. for 21 consecutive days prior to surgery</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Reparixin (DF1681Y, DF1681Y Unbound, DF2243Y, DF2188Y) - CL/F (L/h) at Day 1, CLSS/F (L/h) Day 21)</title>
          <description>The intent of the PK outcomes was not to compare the results between the two cohorts; for this reason results for the PK outcomes are reported for the whole group of the treated patients.&#xD;
CL/F = Apparent oral clearance - for DF1681Y only, calculated as dose/AUCinf.; calculated only when the coefficient of determination R2 in lambda zeta estimation is at least 0.8 and percent AUC extrapolation is less than or equal to 20%.&#xD;
CLss/F = Steady state apparent oral clearance - for DF1681Y only calculated as dose/AUCtau.</description>
          <population>The PK Population consisted of patients who received at least one dose of reparixin and had at least one valid, quantifiable PK parameter. This population was used for PK analyses.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DF1681Y - CL/F - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.173" spread="1.7466"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y - CLSS/F - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.866" spread="0.9086"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y unbound - CL/F - Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7156.189" spread="6334.8463"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DF1681Y unbound - CLSS/F - Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5604.781" spread="2335.8016"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline to Day 21 in Leukocytes Subsets</title>
        <description>The Leukocytes subsets analyzed are the following: Lymphocyte in WBC, Total T cell in lymphocytes, B cells in lymphocytes, T-helper cell in lymphocytes, CTL in lymphocytes, NKT cell in lymphocytes, ADCC NK subsets in lymphocytes, Regulatory NK subsets in lymphocytes, Exhausted NK subsets in lymphocytes, CD56-CD16+ NK subsets in lymphocytes, CD11b in PMNs - IL-8, CD18 in PMNs - IL-8, MFI of CD11b - IL-8, MFI of CD66b - IL-8, MFI of CD18 - IL-8, CD11b in PMNs - US, CD18 in PMNs - US, MFI of CD11b - US, MFI of CD66b - US, MFI of CD18 - US, Percent Monocytes expressing IL6 - IL-8,Percent Monocytes expressing IL1b - IL-8, Percent Monocytes expressing IL8 - IL-8, Percent Monocytes expressing TNFa - IL-8, Percent Neutrophils expressing IL6 - IL-8, Percent Neutrophils expressing IL1b - IL-8, Percent Neutrophils expressing IL8 - IL-8, Percent Neutrophils expressing TNFa - IL-8,Percent Monocytes expressing IL6 - US,Percent Monocytes expressing IL1b - US, etc.</description>
        <time_frame>At Day 21</time_frame>
        <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis</population>
        <group_list>
          <group group_id="O1">
            <title>ER+ and/or PR+/ HER-2 -</title>
            <description>Patients of Group A (estrogen receptor positive (ER+) and/or progesterone receptor positive (PR+)/human epidermal growth factor receptor-2 negative (HER-2-)) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack.</description>
          </group>
          <group group_id="O2">
            <title>ER-/PR-/HER-2-</title>
            <description>Patients of Group B (estrogen receptor negative (ER-)/progesterone receptor negative (PR-)/HER-2-) were given Reparixin 1000 mg (two 500 mg tablets) for 21 consecutive days. Reparixin was administered orally, every six to eight hours t.i.d. preferably with food. However, if the patient was unable to eat, reparixin could still be administered. Reparixin was administered with about 250 mL water and a light meal or snack.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline to Day 21 in Leukocytes Subsets</title>
          <description>The Leukocytes subsets analyzed are the following: Lymphocyte in WBC, Total T cell in lymphocytes, B cells in lymphocytes, T-helper cell in lymphocytes, CTL in lymphocytes, NKT cell in lymphocytes, ADCC NK subsets in lymphocytes, Regulatory NK subsets in lymphocytes, Exhausted NK subsets in lymphocytes, CD56-CD16+ NK subsets in lymphocytes, CD11b in PMNs - IL-8, CD18 in PMNs - IL-8, MFI of CD11b - IL-8, MFI of CD66b - IL-8, MFI of CD18 - IL-8, CD11b in PMNs - US, CD18 in PMNs - US, MFI of CD11b - US, MFI of CD66b - US, MFI of CD18 - US, Percent Monocytes expressing IL6 - IL-8,Percent Monocytes expressing IL1b - IL-8, Percent Monocytes expressing IL8 - IL-8, Percent Monocytes expressing TNFa - IL-8, Percent Neutrophils expressing IL6 - IL-8, Percent Neutrophils expressing IL1b - IL-8, Percent Neutrophils expressing IL8 - IL-8, Percent Neutrophils expressing TNFa - IL-8,Percent Monocytes expressing IL6 - US,Percent Monocytes expressing IL1b - US, etc.</description>
          <population>The Safety Population included all enrolled patients who took at least one dose of study drug reparixin. This population was used for primary endpoints and safety analysis</population>
          <units>percent of total</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Lymphocyte in WBC</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.51" spread="9.099"/>
                    <measurement group_id="O2" value="-3.70" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total T cell in lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.28" spread="4.602"/>
                    <measurement group_id="O2" value="-2.80" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>B cell in lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.678" spread="7.5565"/>
                    <measurement group_id="O2" value="43.190" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-helper cell in lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.44" spread="5.158"/>
                    <measurement group_id="O2" value="-24.90" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CTL in lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.639" spread="5.5106"/>
                    <measurement group_id="O2" value="-24.100" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NKT cell in lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.510" spread="1.5759"/>
                    <measurement group_id="O2" value="0.140" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ADCC NK subsets in lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.727" spread="4.1787"/>
                    <measurement group_id="O2" value="1.430" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Regulatory NK subsets in lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.358" spread="3.2465"/>
                    <measurement group_id="O2" value="0.370" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Exhausted NK subsets in lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.177" spread="1.7006"/>
                    <measurement group_id="O2" value="-0.170" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD56-CD16+ NK subsets in lymphocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.708" spread="1.6772"/>
                    <measurement group_id="O2" value="0.310" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD11b in PMNs - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.48" spread="4.877"/>
                    <measurement group_id="O2" value="-11.60" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD18 in PMNs - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="4.104"/>
                    <measurement group_id="O2" value="2.10" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MFI of CD11b - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.63" spread="2.205"/>
                    <measurement group_id="O2" value="3.50" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MFI of CD66b - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.9" spread="507.79"/>
                    <measurement group_id="O2" value="-929.0" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MFI of CD18 - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="495.89"/>
                    <measurement group_id="O2" value="71.0" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD11b in PMNs - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.56" spread="9.515"/>
                    <measurement group_id="O2" value="-4.20" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CD18 in PMNs - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.758" spread="23.7696"/>
                    <measurement group_id="O2" value="-0.400" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MFI of CD11b - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.84" spread="1.571"/>
                    <measurement group_id="O2" value="-0.30" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MFI of CD66b - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.1" spread="536.54"/>
                    <measurement group_id="O2" value="-757.0" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>MFI of CD18 - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="16"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-105.64" spread="679.547"/>
                    <measurement group_id="O2" value="-47.00" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL6 - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.40590" spread="27.654326"/>
                    <measurement group_id="O2" value="0.52600" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL1b - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.27479" spread="24.364503"/>
                    <measurement group_id="O2" value="0.32600" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL8 - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.35947" spread="3.983235"/>
                    <measurement group_id="O2" value="-0.04400" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing TNFa - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40504" spread="1.906309"/>
                    <measurement group_id="O2" value="-0.39900" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL6 - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.83019" spread="26.145843"/>
                    <measurement group_id="O2" value="0.36340" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL1b - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.24530" spread="32.068081"/>
                    <measurement group_id="O2" value="0.33400" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL8 - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.04596" spread="1.667000"/>
                    <measurement group_id="O2" value="0.05742" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing TNFa - IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35635" spread="2.269023"/>
                    <measurement group_id="O2" value="0.03500" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL6 - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.77675" spread="29.705447"/>
                    <measurement group_id="O2" value="0.26500" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL1b - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.58031" spread="28.862940"/>
                    <measurement group_id="O2" value="1.03400" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL8 - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14087" spread="2.716051"/>
                    <measurement group_id="O2" value="-0.27600" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing TNFa - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.11532" spread="1.333406"/>
                    <measurement group_id="O2" value="0.28200" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL6 - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.50297" spread="21.932274"/>
                    <measurement group_id="O2" value="0.59260" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL1b - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.28329" spread="33.754437"/>
                    <measurement group_id="O2" value="1.36450" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL8 - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.45567" spread="2.053990"/>
                    <measurement group_id="O2" value="0.15020" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing TNFa - US</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46929" spread="2.876200"/>
                    <measurement group_id="O2" value="0.54910" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL6 - LPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.23" spread="8.015"/>
                    <measurement group_id="O2" value="-9.60" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL1b - LPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.18" spread="18.237"/>
                    <measurement group_id="O2" value="27.80" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL8 - LPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.2057" spread="21.72201"/>
                    <measurement group_id="O2" value="-74.3700" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing TNFa - LPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.145" spread="8.8075"/>
                    <measurement group_id="O2" value="-56.400" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL6 - LPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.0310" spread="4.60857"/>
                    <measurement group_id="O2" value="72.3690" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL1b - LPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.68086" spread="5.470114"/>
                    <measurement group_id="O2" value="78.19200" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL8 - LPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.14986" spread="1.844687"/>
                    <measurement group_id="O2" value="1.18700" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing TNFa - LPS</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1497" spread="1.97537"/>
                    <measurement group_id="O2" value="1.7720" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL6 - LPS+IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.42" spread="6.783"/>
                    <measurement group_id="O2" value="1.20" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL1b - LPS+IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.79" spread="14.168"/>
                    <measurement group_id="O2" value="25.90" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing IL8 - LPS+IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.738" spread="12.9421"/>
                    <measurement group_id="O2" value="-76.990" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Monocytes expressing TNFa - LPS+IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.3018" spread="9.97119"/>
                    <measurement group_id="O2" value="-57.9100" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL6 - LPS+IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2629" spread="20.77484"/>
                    <measurement group_id="O2" value="62.7900" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL1b - LPS+IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1980" spread="27.96300"/>
                    <measurement group_id="O2" value="81.6290" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing IL8 - LPS+IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0348" spread="1.81583"/>
                    <measurement group_id="O2" value="1.0010" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Neutrophils expressing TNFa - LPS+IL-8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.0349" spread="1.75308"/>
                    <measurement group_id="O2" value="2.6490" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent FITC eColi Control</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.327" spread="7.7795"/>
                    <measurement group_id="O2" value="-8.500" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent FITC eColi Test</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.056" spread="3.6456"/>
                    <measurement group_id="O2" value="-4.200" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent PMNs unstimulated</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.025" spread="16.3554"/>
                    <measurement group_id="O2" value="28.690" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent PMNs fMLP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.152" spread="18.2092"/>
                    <measurement group_id="O2" value="23.300" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent L-selectin unstimulated</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.341" spread="25.8071"/>
                    <measurement group_id="O2" value="-25.000" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent L-selectin fMLP</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.2845" spread="0.95877"/>
                    <measurement group_id="O2" value="-0.2460" spread="NA">Since the patient is only one, no SD can be calculated</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Lymphocyte in WBC</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6168</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Total T cell in lymphocytes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6168</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>B cell in lymphocytes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1453</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>T-helper cell in lymphocytes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1453</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CTL in lymphocytes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1453</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>NKT cell in lymphocytes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>ADCC NK subsets in lymphocytes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.7634</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Regulatory NK subsets in lymphocytes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5487</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Exhausted NK subsets in lymphocytes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD56-CD16+ NK subsets in lymphocytes</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD11b in PMNs - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1451</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD18 in PMNs - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2779</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MFI of CD11b - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1444</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MFI of CD66b - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1453</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MFI of CD18 - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.9200</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD11b in PMNs - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2779</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CD18 in PMNs - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6164</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MFI of CD11b - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MFI of CD66b - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2032</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>MFI of CD18 - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL6 - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5250</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL1b - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.6706</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL8 - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8312</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing TNFa - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3992</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL6 - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2952</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL1b - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3992</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL8 - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2952</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing TNFa - IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.5250</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL6 - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3992</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL1b - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2952</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL8 - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&gt;0.9999</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing TNFa - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3992</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL6 - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3992</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL1b - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2952</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL8 - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3992</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing TNFa - US</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2952</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL6 - LPS</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2238</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL1b - LPS</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2238</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL8 - LPS</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1543</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing TNFa - LPS</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1547</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL6 - LPS</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1547</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL1b - LPS</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1547</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL8 - LPS</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4314</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing TNFa - LPS</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3153</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL6 - LPS+IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4700</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL1b - LPS+IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1605</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing IL8 - LPS+IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1605</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Monocytes expressing TNFa - LPS+IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1605</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL6 - LPS+IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1547</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL1b - LPS+IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1547</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing IL8 - LPS+IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3153</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent Neutrophils expressing TNFa - LPS+IL-8</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1543</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent FITC eColi Control</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1601</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent FITC eColi Test</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.2368</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent PMNs unstimulated</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.1605</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent PMNs fMLP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.4700</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent L-selectin unstimulated</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.3392</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Percent L-selectin fMLP</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.8080</p_value>
            <p_value_desc>P-Value is based on two-sample t-test or Wilcoxon Rank-Sum test, where appropriate, comparing the 2 study groups.</p_value_desc>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>throughout the study and at OTV (off treatment visit) up to the 30 days after the last dose of reparixin</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Total</title>
          <description>This represents the total safety population of 20 patients</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Epidermolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Incision site haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Incision site pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Post procedural haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pheripheral sensory neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Pier Adelchi Ruffini, MD</name_or_title>
      <organization>Dompé Farmaceutici</organization>
      <phone>+39 (0)2 583831</phone>
      <email>info@dompe.it</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

